Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer

Annals of Surgical Oncology(2017)

引用 11|浏览1
暂无评分
摘要
Background Although transplant benefit appears superior for patients with advanced hepatocellular cancer (HCC), liver transplantation remains limited to selected low-risk HCC patients to keep their outcomes similar to heterogeneous group of non-HCC patients. The purpose of this study was to assess the rationale for current policy of restricting access to liver transplantation to minority of HCC patients based on utility principle. Methods This retrospective cohort study comprised 1246 liver transplant recipients, including 206 HCC and 1040 non-HCC patients. Patient survival was the primary outcome measure. Patients with HCC and benign diseases were divided into low-, moderate-, and high-risk subgroups basing on independent risk factors for disease-free survival and model for end-stage liver disease (MELD) score (<30, 30–40, >40), respectively. Results MELD ( p < 0.001) and presence of HCC ( p = 0.008) were independent risk factors for early and late mortality, respectively. Total tumor volume ( p = 0.008) and alpha-fetoprotein ( p = 0.013) were independent predictors of recurrence and mortality used for division of HCC patients into low-, moderate-, and high-risk subgroups, with disease-free survival rates of 74.9% (5 years), 51.7% (5 years), and 8.0% (3 years), respectively ( p < 0.001). There were no differences in 5-year overall survival between low-risk HCC (74.9%) and non-HCC (81.9%) patients ( p = 0.210), moderate-risk HCC (63.3%) and non-HCC (68.0%) patients ( p = 0.372), and high-risk HCC (55.0%) and non-HCC (56.0%) patients ( p = 0.559). Conclusions The principle of utility is unequally applied for restriction of access to liver transplantation for HCC patients. The results provide rationale for discussion on reinitiation of liver transplantation for advanced HCCs.
更多
查看译文
关键词
Hepatocellular Cancer,Model For End-stage Liver Disease (MELD),Total Tumor Volume,Advanced HCCs,Transplant Benefit
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要